Murray J. Towle
- Oncology top 5%
- Molecular Biology
- Organic Chemistry top 10%
- Pharmacology top 5%
- Cell Biology top 10%
- Co-authors
- Bruce A. LittlefieldMelvin J. YuYoshito KishiGalina KuznetsovHongsheng ChengKaren TenDykeKenneth A. AultDiana Liu
- Topics
- Cancer Treatment and Pharmacology (9 papers)HER2/EGFR in Cancer Research (5 papers)Microbial Natural Products and Biosynthesis (4 papers)
- Cited by
- OncologyBiotechnologyToxicology
- Partner nations
- United StatesJapanItaly
In The Last Decade
Murray J. Towle
24 papers receiving 1.1k citations
Peers
Comparison fields: 5 of 82
- Oncology 509
- Molecular Biology 440
- Organic Chemistry 211
- Pharmacology 178
- Cell Biology 162
Countries citing papers authored by Murray J. Towle
This map shows the geographic impact of Murray J. Towle's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Murray J. Towle with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Murray J. Towle more than expected).
Fields of papers citing papers by Murray J. Towle
This network shows the impact of papers produced by Murray J. Towle. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Murray J. Towle. The network helps show where Murray J. Towle may publish in the future.
Co-authorship network of co-authors of Murray J. Towle
This figure shows the co-authorship network connecting the top 25 collaborators of Murray J. Towle. A scholar is included among the top collaborators of Murray J. Towle based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Murray J. Towle. Murray J. Towle is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 27 | |
| 2 | 1 | |
| 3 | Broad spectrum preclinical antitumor activity of eribulin (Halaven(R)): optimal effectiveness under intermittent dosing conditions. | 38 |
| 4 | 75 | |
| 5 | 12 | |
| 6 | 16 | |
| 7 | 16 | |
| 8 | 111 | |
| 9 | 2 | |
| 10 | 85 | |
| 11 | Abstract #3687: In vivo anticancer activity of E6201, a novel MEK1 inhibitor, against BRAF-mutated human cancer xenografts | 3 |
| 12 | In vitro and in vivo anticancer activities of synthetic (-)-laulimalide, a marine natural product microtubule stabilizing agent. | 63 |
| 13 | A 96-well plate cell-based assay to quantify undesired cytotoxic effects against quiescent non-dividing cells | 3 |
| 14 | 56 | |
| 15 | 114 | |
| 16 | 45 | |
| 17 | 22 | |
| 18 | 24 | |
| 19 | 17 | |
| 20 | 48 |
About Murray J. Towle
Murray J. Towle is a scholar working on Oncology, Toxicology and Pharmacology, having authored 24 papers that have together received 1.1k indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (9 papers), HER2/EGFR in Cancer Research (5 papers) and Microbial Natural Products and Biosynthesis (4 papers). The work is most often cited by research in Oncology (509 citations), Biotechnology (150 citations) and Toxicology (39 citations). Murray J. Towle has collaborated with scholars based in United States, Japan and Italy. Frequent co-authors include Bruce A. Littlefield, Melvin J. Yu, Yoshito Kishi, Galina Kuznetsov, Hongsheng Cheng, Karen TenDyke, Kenneth A. Ault, Diana Liu, Takanori Kawamura and Boris M. Seletsky. Their work appears in journals such as New England Journal of Medicine, Nucleic Acids Research and The Journal of Experimental Medicine.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.